At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. 

Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com. 

Life Sciences

Therapeutics

Lykos Therapeutics (formerly MAPS PBC)

Amy Emerson

E. Blair Clark-Schoeb

Allison Rosenthal

William Stewart

Michelle Lacy

Kacy Hutchison

Andrew Septimus

Dr. Berra Yazar-Klosinski

Berra Yazar - Klosinski

Michael Mullette

Joy Sun Cooper

Blair Clark - Schoeb

The Clinical Research and Development team at Lykos Therapeutics is dedicated to advancing the science of psychedelic-assisted therapies for mental health treatment. This interdisciplinary team conducts rigorous clinical trials, evaluates therapeutic effectiveness, and ensures adherence to study protocols, all aimed at developing innovative treatment options. By combining expertise in psychotherapy, research, and medical science, they drive the translation of groundbreaking research into practical therapies that address mental health challenges.

Clinical Research and Development

Financial and Administrative Support

Leadership Team

Clinical Research and Development

About

Team members

Other teams at Lykos Therapeutics (formerly MAPS PBC)

Financial and Administrative Support

Leadership Team